Gastric Cancer Market
Global Gastric Cancer Market Size, Share & Trends Analysis Report by Testing Type (Chest X-Ray, Computed Tomography (CT OR CAT) Scan, Laparoscopy, MRI Scan, PET Scan, and Others) By Treatment Type (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, and Immunotherapy) By End-User (Hospitals & Clinics, Specialized Cancer Treatment Centers, and Others) Forecast 2021-2027 Update Available - Forecast 2024-2030
The global market for gastric cancer is projected to have a considerable CAGR of around 6.8% during the forecast period. Gastric cancer is one of the most common forms of cancer across the globe. In gastric cancer, the malignant cells form in the lining of the stomach and develop slowly over many years. Bacterium Helicobacter pylori is a stomach infection that is one of the primary factors for the occurrence of gastric cancer. The high prevalence of gastrointestinal stromal tumours, carcinoid tumors, and lymphoma is one of the major factors for augmenting the treatment market of gastric cancer. An increase in the number of cancer treatment facilities across the globe is another major factor for the growth of the market. According to the American Cancer Society’s estimates for stomach cancer (also known as gastric cancer) in the US for 2021, there are about 26,560 new cases of stomach cancer (16,160 in men and 10,400 in women) are diagnosed, and about 11,180 people are died due to this type of cancer (6,740 men and 4,440 women) are registered. The growing elderly population, technological advancement and rising incidence and prevalence rate of gastric cancer are boosting the stomach cancer market across the globe.
However, the high cost of therapy and commercially less availability of drugs for the treatment of stomach cancer, and regulatory procedures for approving the complex nature of radiation devices are projected to hamper the market growth. Besides, the development of a new cancer screening technique and continuous R&D in drug innovation for better treatment is expected to create lucrative opportunities in the global gastric cancer market.
Segmental Outlook
The global gastric cancer market is segmented based on testing type, treatment type and end-users. Based on testing type, the market further segmented into chest x-ray, computed tomography (CT or CAT) scan, laparoscopy, magnetic resonance imaging (MRI) scan, positron emission tomography (PET) scan and Others. Similarly, on the basis of treatment type, the market is classified into chemotherapy, radiation therapy, surgery, targeted therapy, and immunotherapy. Among these, the targeted therapy segment is expected to show a significant growth rate during the forecast period. Delivery of advanced techniques including enzyme therapy and stem cell therapy is the primary factor for growth in the targeted therapy market. Targeted therapy tends to work in some cases where standard chemotherapy does not work. In such cases, trastuzumab, a targeted therapy drug, is given with chemotherapy. Based on end-user, the market is classified into hospitals & clinics, specialized cancer treatment centers and others.
Global Gastric Cancer Market Share by Treatment Type, 2020 (%)
Chemotherapy projected to hold the largest share in Gastric Cancer Market
Based on treatment type, the chemotherapy segment is projected to dominate the global gastric cancer market by acquiring the largest market share during the forecast period. The chemotherapy is used to slow down the formation of cancer cells. It is considered the most preferred and useful treatment for cancer that has spread to organs beyond where it started. Chemotherapy (chemo) uses anti-cancer drugs that are injected into a vein (through an IV line or central venous catheter) or given by mouth as pills. These drugs enter the bloodstream and reach all areas of the body to control the wide spreading of cancer cells. These therapies can be given to patients in two forms, before surgery and after surgery. Chemo is given before surgery for stomach cancer known as neoadjuvant treatment, and chemo after surgery is known as adjuvant treatment. The rising prevalence of gastric cancer coupled with geriatric populations creates the demand for such type of advanced therapies, that further led to the development of the market.
Regional Outlook
Geographically, the global Gastric Cancer market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, the Asia-Pacific region is expected to grow at a considerable CAGR during the forecast period. Growing disposable income, awareness and healthcare spending are the major factor driving the growth of the gastric cancer market in the region. The rising prevalence of gastric cancer in various countries such as China, Japan, South Korea will create significant market growth for gastric cancer in the region.
Global gastric cancer market growth, by region 2021-2027
North America further estimated to Dominate the Gastric Cancer Market
Geographically, North America held the largest share in the global gastric cancer market in 2020, and it is anticipated to dominate the market during the forecast period. In North America, the US holds the largest market share. The availability of cancer treatment drugs and development in the healthcare sector coupled with advanced treatments and technologies is the major factor augmenting the growth of the market. The rising prevalence of gastric cancer, large patients’ pools, and growing geriatric population also accelerating the market growth by increasing demands for advanced treatments. According to the National Cancer Institute, in 2021, there are 26,560 new gastric cancer cases are estimated, which is 1.4% of the total cases, and 11,180 deaths are due to gastric cancer are estimated, which is 1.8% of the total mortalities.
Market Players Outlook
The key players in the gastric cancer market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis International AG, among others. These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions to generate more revenue and to remain competitive in the market. For instance, in August 2020, Pieris Pharmaceuticals, Inc, a clinical-stage biotechnology company and Eli Lilly and Co., came into a clinical trial collaboration supply agreement to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a VEGFR2 antagonist and paclitaxel for the second-line treatment of patients with HER2-positive gastric cancer in a phase 2 study.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Gastric Cancer market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Gastric Cancer Industry
• Recovery Scenario of Global Gastric Cancer Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Gastric Cancer Market, By Testing Type
5.1.1. Chest X-Ray
5.1.2. Computed Tomography (CT OR CAT) Scan
5.1.3. Laparoscopy
5.1.4. Magnetic Resonance Imaging (MRI) Scan
5.1.5. Positron Emission Tomography (PET) Scan
5.1.6. Others (Upper Gastrointestinal (GI) Series)
5.2. Global Gastric Cancer Market, By Treatment Type
5.2.1. Chemotherapy
5.2.2. Radiation Therapy
5.2.3. Surgery
5.2.4. Targeted Therapy
5.2.5. Immunotherapy
5.3. Global Gastric Cancer Market, By End-Users
5.3.1. Hospitals & Clinics
5.3.2. Specialized Cancer Treatment Centers
5.3.3. Others (Ambulatory Surgical Centers)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Russia
6.2.7. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korean
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East& Africa
7. Company Profiles
7.1. Abbott Laboratories
7.2. ASLAN Pharmaceuticals Pte Ltd.
7.3. AstraZeneca PLC
7.4. Athenex, Inc.
7.5. Bayer AG
7.6. Biogen Inc.
7.7. Bristol Myers Squibb Co.
7.8. Celltrion, Inc.
7.9. Danaher Corp.
7.10. Eli Lilly and Co.
7.11. F. Hoffmann-La Roche Ltd.
7.12. GlaxoSmithKline plc
7.13. ImmunoGen, Inc.
7.14. Ipsen Pharma
7.15. Merck & Co., Inc.
7.16. Novartis International AG
7.17. Otsuka Holdings Co. Ltd.
7.18. Oncolytics Biotech, Inc.
7.19. Pacific Edge Ltd.
7.20. Pfizer Inc.
7.21. Thermo Fisher Scientific Inc.
1. GLOBAL GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TESTING TYPE, 2020-2027 ($ MILLION)
2. GLOBAL CHEST X-RAY FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL COMPUTED TOMOGRAPHY (CT OR CAT) SCAN FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL LAPAROSCOPY FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SCAN FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SCAN FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL OTHERS FOR GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
9. GLOBAL CHEMOTHERAPY IN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL RADIATION THERAPY IN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL SURGERY IN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL TARGETED THERAPY IN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL IMMUNOTHERAPYIN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
15. GLOBAL HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL SPECIALIZED CANCER TREATMENT CENTRES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
19. NORTH AMERICAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
20. NORTH AMERICAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TESTING TYPE, 2020-2027 ($ MILLION)
21. NORTH AMERICAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
22. NORTH AMERICAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027 ($ MILLION)
23. EUROPEAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
24. EUROPEAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TESTING TYPE, 2020-2027 ($ MILLION)
25. EUROPEAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
26. EUROPEAN GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027 ($ MILLION)
27. ASIA-PACIFIC GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
28. ASIA-PACIFIC GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TESTING TYPE, 2020-2027 ($ MILLION)
29. ASIA-PACIFIC GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2020-2027 ($ MILLION)
30. ASIA-PACIFIC GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027 ($ MILLION)
31. REST OF THE WORLD GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
32. REST OF THE WORLD GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TESTING TYPE, 2020-2027 ($ MILLION)
33. REST OF THE WORLD GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
34. REST OF THE WORLD GASTRIC CANCER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL GASTRIC CANCER MARKET, 2020-2027 (% MILLION)
2. IMPACT OF COVID-19 ON GLOBAL GASTRIC CANCER MARKET BY SEGMENT, 2020-2027 (% MILLION)
3. RECOVERY OF GLOBAL GASTRIC CANCER MARKET, 2020-2027 (%)
4. GLOBAL GASTRIC CANCER MARKET SHARE BY TESTING TYPE,2020 VS 2027 (%)
5. GLOBAL GASTRIC CANCER MARKET SHARE BY TREATMENT TYPE, 2020 VS 2027 (%)
6. GLOBAL GASTRIC CANCER MARKET SHARE BY END-USERS, 2020 VS 2027 (%)
7. GLOBAL GASTRIC CANCER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL CHEST X-RAY FOR GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL COMPUTED TOMOGRAPHY (CT OR CAT) SCAN FOR GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL LAPAROSCOPY FOR GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) SCAN FOR GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) SCAN FOR GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL CHEMOTHERAPY IN GASTRIC MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL RADIATION THERAPY IN GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL SURGERY IN GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL TARGETED THERAPY IN GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL IMMUNOTHERAPYIN GASTRIC CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL HOSPITALS & CLINICS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL SPECIALIZED CANCER TREATMENT MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
20. GLOBAL OTHER END-USERS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
21. US GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
22. CANADA GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
23. UK GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
24. FRANCE GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
25. GERMANY GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
26. ITALY GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
27. SPAIN GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
28. REST OF EUROPE GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
29. INDIA GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
30. CHINA GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
31. JAPAN GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
32. SOUTH KOREA GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
33. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET SIZE, 2020-2027 ($ MILLION)
34. REST OF THE WORLD GASTRIC CANCER MARKET SIZE, 2021-2027($ MILLION
